Washington, DC-To improve FDA's ability to respond to terrorist attacks, acting commissioner Bernard Schwetz tapped Janet
Woodcock, director of the Center for Drug Evaluation and Research (CDER), to establish a formal crisis management program
for the agency. Woodcock moved to the commissioner's office in November to develop a program to better track and coordinate
FDA responses to terrorism. She will
- coordinate FDA actions with those of other government agencies
- develop contingency plans in case FDA becomes incapacitated
- prepare a long-range counter-terrorism program as part of FDA's permanent crisis management effort.
Woodcock is working with Andrea Meyerhoff, former counter-bioterrorism coordinator in FDA's Office of Science Coordination
& Communications. Other key players are Kathryn Zoon, director of the Center for Biologics Evaluation and Research, who oversees
anti-bioterrorism efforts for vaccines, the nation's blood supply, and biotech therapies,and Dianne Murphy, head of CDER's
new Office of Pediatric Drug Development & Special Initiatives.
Woodcock may also work with former FDA acting commissioner Michael Friedman, who recently joined PhRMA to serve as industry's
counter-bioterrorism spokesman. A physician, former cancer researcher, and now senior vice-president at Pharmacia, Friedman
will head industry efforts to gain liability protection for biological warfare therapies and to provide the Department of
Health and Human Services with information about available medicines and the capacity to make new ones. Friedman's assignment
reflects industry efforts to visibly step up anti-bioterrorism responses. In October, corporate CEOs formed a PhRMA task force
on emergency preparedness headed by Aventis CEO Richard Markham. The group told HHS Secretary Tommy Thompson that it is ready
to provide all the medicines and vaccines the government needs, and Friedman is forming a scientific task force to meet regularly
with government experts to evaluate current research and the need for new products and initiatives.
One proposal is to use industry's vast sales force to inform doctors how to treat conditions created by bioterrorism and other
public health threats. The PhRMA CEO group suggested such an initiative in a recent meeting with the new Office of Homeland
Security Director Tom Ridge. Companies say they will teach reps to deliver information about proper medical care, even if
it means touting a competitor's product. Ridge said he'd consider the idea, but because that would open doctors' doors to
often maligned sales forces, it has prompted strong opposition from patient advocates and healthcare providers.Woodcock says she plans to return to CDER in a few months. Meanwhile, her deputy, Steven Galson, will serve as CDER's acting
director. Galson has already established a new Office of Pharmacoepidemiology & Statistical Science and is preparing a risk
management action plan for pharmaceuticals. In addition, FDA is forming a new pharmaceutical risk management advisory committee
to provide expert advice on safety issues.
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA